Over the past two decades, the beef industry has made substantial progress in food safety, with focused, science-driven interventions and widespread adoption of screening protocols dramatically reducing the prevalence of E. coli O157:H7 across the US beef supply chain.

This progress is no accident. It is the result of coordinated effort, increased regulatory action, and sustained investment in operational excellence. But as we look ahead, we face a new and equally important challenge: adapting our detection strategies to reflect the broader landscape of Shiga toxin-producing E. coli (STEC). Emerging serogroups, evolving epidemiology, and the possibility of increasing regulatory scrutiny mean that the industry is once again at a crossroads. And just as it did with E. coli O157:H7, it will need to evolve.

A new STEC reality: What we’re missing by staying narrow

While E. coli O157:H7 remains a serious concern, it no longer accounts for the majority of clinical STEC infections. Non-O157 serogroups, including O26, O45, O103, O111, O121 and O145, have been linked to numerous foodborne illness outbreaks, and all six are now classified by FSIS as adulterants in raw beef products.

However, testing practices across the industry remain uneven. Many operations continue to focus exclusively on E. coli O157:H7, whether due to legacy infrastructure, regulatory minimums, or understandable concerns about introducing complexity and cost.

That caution is reasonable. Changing established protocols—especially ones that have supported a demonstrable reduction in illness—is never a simple decision. But the science is clear: E. coli risk no longer begins and ends with O157. Failing to adapt carries risk for brands and consumers alike.

The operational barrier: Unconfirmed positives and workflow friction

Among the most common hesitations around broader STEC testing is the operational burden created by current PCR-based screens. While most commercial assays are capable of detecting the presence of stx and eae genes—both markers of virulence—they often do so without the ability to confirm that these genes are co-located within the same bacterial cell.

As a result, facilities are often confronted with high numbers of presumptive positives that fail to confirm. In practical terms, this means:

• Product may be held longer than necessary while awaiting confirmatory testing
• Confirmatory workflows add cost and time, particularly when outsourced
• Operational teams spend resources managing false alarms instead of true risks

In some cases, these inefficiencies have disincentivized plants from implementing full-spectrum STEC testing, even when there is awareness of its public health value.

A targeted solution: Introducing PEC markers

Recent advancements in molecular diagnostics have made it possible to refine STEC screening by detecting co-localization of virulence genes within a single E. coli organism. While most commercial PCR assays detect the presence of stx and eae genes independently, these results alone do not confirm whether both genes are present in the same cell. This is a critical factor in determining true pathogenic potential.

To address this limitation, bioMérieux has developed and incorporated a novel molecular target into PCR assays to detect pathogenic E. coli strains more specifically. These assays are designed to flag samples where stx and eae genes co-occur alongside additional genomic markers associated with high-virulence STEC. This approach helps distinguish viable, high-risk organisms from incidental environmental signals or free DNA, significantly reducing unconfirmed positives.

In validation studies across multiple laboratories, including work conducted with USDA's Agricultural Research Service, bioMérieux’s assays using this genomic co-localization strategy were shown to be useful and approximately doubled the specificity for EHEC screening. This has meaningful implications for operational efficiency: fewer unnecessary holds, reduced confirmatory testing, and faster product release without compromising safety.

bioMérieux’s GENE-UP Pathogenic E. coli (PEC) assay was adopted in 2024 by the USDA FSIS as part of its official screening protocol for adulterant STEC, following inclusion in the Microbiology Laboratory Guidebook. This represents the first widely validated application of gene co-localization to improve STEC specificity in routine screening.

The assay is compatible with existing enrichment and PCR workflows. As the industry considers expanding beyond O157-based detection, tools like these offer a practical bridge, by enabling more precise identification of true adulterant STEC without adding undue complexity to laboratory operations.

Supporting progress, not replacing it

To be clear, the beef industry’s current approach to E. coli O157:H7 has worked. The incidence of E. coli O157:H7 illness has declined, and outbreak-linked recalls have become rarer. That track record should be applauded.

But the threat profile has changed. Pathogens don’t stand still, and neither can our detection methods. Innovations like PEC are designed to complement and enhance current methods, enabling food safety programs to be both broader and more precise.

Just as the industry once came together to tackle E. coli O157:H7, now is the time to take the next step. The tools are ready. The data are clear. And with thoughtful implementation, this next evolution can protect public health, minimize operational disruption and reinforce consumer confidence—all without sacrificing the hard-won gains of the past.